FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890427308> ?p ?o ?g. }

• W2890427308 abstract "4083 Background: Combined use of sorafenib and local therapy for treating unresectable hepatocellular carcinoma (HCC) is not well established. Notably, most common cause of death in HCC is liver failure, therefore we tested the promise of controlling the local tumors even in the setting of advanced/metastatic disease to improve survival. Our study aimed to assess the efficacy and safety of combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) in unresectable HCC defined as Barcelona Clinic Liver Cancer class C. Methods: Between October 2013 and August 2016 we enrolled 40 advanced stage HCC patients, 38 patients were treated with sorafenib followed (after 4 weeks) with Y90 RMS at MD Anderson Cancer Center. Survival analysis was done to evaluate median overall survival (OS) and progression-free survival (PFS). We used modified Response Evaluation Criteria in Solid Tumors (RECIST) to assess response to treatment and the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 to evaluate the grading of treatment related toxicity. Results: The majority of our patients were males (74%), white (47%), 66% of patients had underlying liver cirrhosis, 26% had vascular invasion, and 26% had extrahepatic disease. The estimated median OS and 95% confidence interval (CI) in months was 18.46 (12.29 – NA) and the estimated PFS was 12.29 months (5.72 – 18.79). Stable disease (SD) was observed in 44.74% of patients, while 28.95% achieved partial response (PR). Grade III-IV adverse events included fatigue (n = 3), hyperbilirubinemia (n = 2), thrombocytopenia (n = 1), proteinuria (n = 1), hyponatremia (n = 1), elevated liver enzymes (n = 4), hypertension (n = 4), diarrhea (n = 1), nausea (n = 1) and vomiting (n = 2). Conclusions: This is the first prospective study to evaluate sorafenib followed by Y90 in HCC. Our study included patients with metastatic HCC and showed that combined use of sorafenib and Y90 was tolerable and was associated with longer OS and PFS compared to previous studies which evaluated sorafenib alone. However, future randomized phase III studies are warranted to assess sorafenib+/-Y90 in metastatc disease setting. Clinical trial information: NCT01900002." @default.
• W2890427308 created "2018-09-27" @default.
• W2890427308 creator A5001295453 @default.
• W2890427308 creator A5002142766 @default.
• W2890427308 creator A5018387509 @default.
• W2890427308 creator A5032970786 @default.
• W2890427308 creator A5034845901 @default.
• W2890427308 creator A5035371911 @default.
• W2890427308 creator A5035707976 @default.
• W2890427308 creator A5042362382 @default.
• W2890427308 creator A5043534982 @default.
• W2890427308 creator A5046065062 @default.
• W2890427308 creator A5060113793 @default.
• W2890427308 creator A5067227071 @default.
• W2890427308 creator A5089093200 @default.
• W2890427308 date "2017-05-20" @default.
• W2890427308 modified "2023-09-28" @default.
• W2890427308 title "A phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C." @default.
• W2890427308 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4083" @default.
• W2890427308 hasPublicationYear "2017" @default.
• W2890427308 type Work @default.
• W2890427308 sameAs 2890427308 @default.
• W2890427308 citedByCount "1" @default.
• W2890427308 countsByYear W28904273082017 @default.
• W2890427308 crossrefType "journal-article" @default.
• W2890427308 hasAuthorship W2890427308A5001295453 @default.
• W2890427308 hasAuthorship W2890427308A5002142766 @default.
• W2890427308 hasAuthorship W2890427308A5018387509 @default.
• W2890427308 hasAuthorship W2890427308A5032970786 @default.
• W2890427308 hasAuthorship W2890427308A5034845901 @default.
• W2890427308 hasAuthorship W2890427308A5035371911 @default.
• W2890427308 hasAuthorship W2890427308A5035707976 @default.
• W2890427308 hasAuthorship W2890427308A5042362382 @default.
• W2890427308 hasAuthorship W2890427308A5043534982 @default.
• W2890427308 hasAuthorship W2890427308A5046065062 @default.
• W2890427308 hasAuthorship W2890427308A5060113793 @default.
• W2890427308 hasAuthorship W2890427308A5067227071 @default.
• W2890427308 hasAuthorship W2890427308A5089093200 @default.
• W2890427308 hasConcept C126322002 @default.
• W2890427308 hasConcept C127413603 @default.
• W2890427308 hasConcept C143998085 @default.
• W2890427308 hasConcept C146357865 @default.
• W2890427308 hasConcept C151730666 @default.
• W2890427308 hasConcept C189942447 @default.
• W2890427308 hasConcept C191897082 @default.
• W2890427308 hasConcept C192562407 @default.
• W2890427308 hasConcept C206394296 @default.
• W2890427308 hasConcept C2778019345 @default.
• W2890427308 hasConcept C2778695046 @default.
• W2890427308 hasConcept C2779851234 @default.
• W2890427308 hasConcept C42360764 @default.
• W2890427308 hasConcept C531131001 @default.
• W2890427308 hasConcept C71924100 @default.
• W2890427308 hasConcept C86803240 @default.
• W2890427308 hasConceptScore W2890427308C126322002 @default.
• W2890427308 hasConceptScore W2890427308C127413603 @default.
• W2890427308 hasConceptScore W2890427308C143998085 @default.
• W2890427308 hasConceptScore W2890427308C146357865 @default.
• W2890427308 hasConceptScore W2890427308C151730666 @default.
• W2890427308 hasConceptScore W2890427308C189942447 @default.
• W2890427308 hasConceptScore W2890427308C191897082 @default.
• W2890427308 hasConceptScore W2890427308C192562407 @default.
• W2890427308 hasConceptScore W2890427308C206394296 @default.
• W2890427308 hasConceptScore W2890427308C2778019345 @default.
• W2890427308 hasConceptScore W2890427308C2778695046 @default.
• W2890427308 hasConceptScore W2890427308C2779851234 @default.
• W2890427308 hasConceptScore W2890427308C42360764 @default.
• W2890427308 hasConceptScore W2890427308C531131001 @default.
• W2890427308 hasConceptScore W2890427308C71924100 @default.
• W2890427308 hasConceptScore W2890427308C86803240 @default.
• W2890427308 hasLocation W28904273081 @default.
• W2890427308 hasOpenAccess W2890427308 @default.
• W2890427308 hasPrimaryLocation W28904273081 @default.
• W2890427308 isParatext "false" @default.
• W2890427308 isRetracted "false" @default.
• W2890427308 magId "2890427308" @default.
• W2890427308 workType "article" @default.